// App-Quantinova.ai

e11547 : Two different doses of fulvestrant (F) as second- or further-line hormone therapy (HT) in elderly patients with metastatic breast cancer (MBC).

Researchers

Presenter

  • Alessandro Comandone

Principal Investigators

  • Cristiano Oliva

  • Paolo Pochettino

  • Ferdinando Garetto

  • Davide Ottaviani

  • Maria Luisa Sartori

  • Elena Giubellino

  • Paola Bergnolo

Medical Centers

  • Ospedale Gradenigo, Torino, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Bone metastases

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Anastrozole

  • Fulvestrant

  • Tamoxifen citrate

Outcome

  • Positive

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved